|
⚲
|
| Keyboard |
| Jerel Davis | |
|---|---|
| Firm | |
| Address | c/o Santa Ana Bio, Inc 1105 Atlantic Ave, Suite 104 Alameda, CA 94501 |
| Source |
| Associated Funds | Form D | Role | 2011 - 2026 | Raised | AUM |
|---|---|---|---|---|---|
| Santa Ana Bio Inc | 021-516165 | Director | 20.0 M of 125.0 M |
||
| Versant Venture Capital SPV I SAB LP | 021-512829 | Executive Officer | 5.0 M of 5.0 M |
||
| Firefly Bio Inc | 021-508629 | Director | 40.0 M of 72.0 M |
||
| Tentarix Biotherapeutics LP | 021-491553 | Director | 35.0 M of 35.0 M |
||
| Santa Ana Bio Inc | 021-474441 | Director | 35.3 M of 70.3 M |
||
| Rayzebio Inc | 021-459654 | Director | 167.9 M of 167.9 M |
||
| Ventus Therapeutics US Inc | 021-433406 | Director | 70.0 M of 140.0 M |
||
| Turnstone Biologics Corp | 021-406191 | Director | 80.0 M of 80.0 M |
||
| Rayzebio Inc | 021-402339 | Director | 108.5 M of 108.5 M |
||
| Santa Ana Bio Inc | 021-401289 | Executive Officer | 8.0 M of 42.0 M |
||
| Ventus Therapeutics US Inc | 021-395752 | Director | 100.0 M of 100.0 M |
||
| Graphite Bio Inc | 021-392907 | Director | 150.7 M of 150.7 M |
||
| Rayzebio Inc | 021-381852 | Director | 105.0 M of 105.0 M |
||
| Rayzebio Inc | 021-380104 | Director | 15.0 M of 45.0 M |
||
| Chinook Therapeutics US Inc | 021-378507 | Director | 115.0 M of 115.0 M |
||
| Tentarix Biotherapeutics LP | 021-375611 | Director | 8.0 M of 50.0 M |
||
| Ventus Therapeutics US Inc | 021-366465 | Director | 16.8 M of 60.1 M |
||
| Chinook Therapeutics US Inc | 021-347663 | Director | 65.0 M of 65.0 M |
||
| Northern Mosaic LP | 021-343083 | Director | 7.3 M of 7.3 M |
||
| Turnstone Biologics Corp | 021-330976 | Director | 42.1 M of 42.1 M |
||
| Mistral Therapeutics Inc | 021-315373 | Director | 25.9 M of 59.3 M |
||
| Versant Voyageurs I Feeder LP | 021-310903 | Director | 20.0 M of 20.0 M |
||
| Travus Therapeutics Inc | 021-266753 | Director | 0.8 M of 2.2 M |
||
| Inception IBD Inc | 021-253915 | Director | 6.9 M of 19.1 M |
||
| Laguna Pharmaceuticals Inc | 021-244746 | Director | 4.5 M of 4.7 M |
||
| Chanrx Corp | 021-234194 | Director | 16.6 M of 31.9 M |
||
| Versant Venture Management LLC | |||||
| Versant Vantage III LP | 021-461398 | Executive Officer | 298.7 M of 298.7 M |
295.6 M | |
| Versant Venture Capital IX LP | 021-461417 | Executive Officer | 600.4 M of 600.4 M |
586.2 M | |
| Versant Voyageurs III LP | 021-461406 | Executive Officer | 300.2 M of 300.2 M |
311.8 M | |
| Versant Vantage II LP | 021-380952 | Executive Officer | 253.9 M of 253.9 M |
249.7 M | |
| Versant Venture Capital VIII LP | 021-380948 | Executive Officer | 560.2 M of 560.2 M |
886.9 M | |
| Versant Voyageurs II LP | 021-380951 | Executive Officer | 140.1 M of 140.1 M |
169.0 M | |
| Versant Vantage I LP | 021-334361 | Director | of 150.0 M |
69.9 M | |
| Versant Venture Capital VII LP | 021-321509 | Director | 600.0 M of 600.0 M |
676.7 M | |
| Versant Voyageurs I LP | 021-346429 | Director | 102.2 M of 102.2 M |
87.8 M | |
| Versant Venture Capital VI LP | 021-273788 | Director | 400.0 M of 400.0 M |
275.9 M | |
| Related People Network |
|---|
| Network #136 at Versant Venture Management LLC — files alongside 31 co-filers |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Turnstone Biologics Corp TSBX
Common Stock
|
2025-08-08 | Tender | 90,888 | ||
|
Turnstone Biologics Corp TSBX
Common Stock
|
2025-08-08 | Tender | 274,990 | ||
|
Turnstone Biologics Corp TSBX
Common Stock
|
2025-08-08 | Tender | 82,006 | ||
|
Turnstone Biologics Corp TSBX
Common Stock
|
2025-08-08 | Tender | 207,486 | ||
|
Turnstone Biologics Corp TSBX
Common Stock
|
2025-08-08 | Tender | 2,726,322 | ||
|
Turnstone Biologics Corp TSBX
Stock Option (Right to Buy) · derivative
|
2024-06-03 | Grant | 12,770 | $0.00 | |
|
Turnstone Biologics Corp TSBX
Stock Option (Right to Buy) · derivative
|
2023-10-16 | Grant | 25,540 | $0.00 | |
|
Chinook Therapeutics Inc KDNY
Common Stock
|
2023-08-11 | Disposed to issuer | 719,104 | ||
|
Chinook Therapeutics Inc KDNY
Common Stock
|
2023-08-11 | Disposed to issuer | 2,105,107 | ||
|
Chinook Therapeutics Inc KDNY
Common Stock
|
2023-08-11 | Disposed to issuer | 210,996 | ||
|
Chinook Therapeutics Inc KDNY
Stock Option (Right to Buy) · derivative
|
2023-08-11 | Disposed to issuer | 5,948 | $23.19 | 137,934 |
|
Chinook Therapeutics Inc KDNY
Stock Option (Right to Buy) · derivative
|
2023-08-11 | Disposed to issuer | 13,300 | $26.12 | 347,396 |
|
Chinook Therapeutics Inc KDNY
Stock Option (Right to Buy) · derivative
|
2023-08-11 | Disposed to issuer | 23,522 | $25.23 | 593,460 |
|
Chinook Therapeutics Inc KDNY
Common Stock
|
2023-08-11 | Disposed to issuer | 447,013 | ||
|
Turnstone Biologics Corp TSBX
Series A Preferred Stock · derivative
|
2023-07-25 | Conversion | 237,575 | $0.00 | |
|
Turnstone Biologics Corp TSBX
Series A Preferred Stock · derivative
|
2023-07-25 | Conversion | 263,349 | $0.00 | |
|
Turnstone Biologics Corp TSBX
Series A Preferred Stock · derivative
|
2023-07-25 | Conversion | 601,077 | $0.00 | |
|
Turnstone Biologics Corp TSBX
Series A Preferred Stock · derivative
|
2023-07-25 | Conversion | 7,897,999 | $0.00 | |
|
Turnstone Biologics Corp TSBX
Common Stock
|
2023-07-25 | Buy | 6,575 | $12.00 | 78,900 |
|
Turnstone Biologics Corp TSBX
Common Stock
|
2023-07-25 | Buy | 15,028 | $12.00 | 180,336 |
| showing 20 of 200 most recent transactions | |||||